In adults ages 18 and older with acquired HO
IMCIVREE has been shown to deliver significant, clinically meaningful, and sustained results
Actor portrayals
How was IMCIVREE studied?
IMCIVREE was studied over the course of 1 year in a clinical study that included 142 children and adults aged 4 years and older with acquired HO. People were randomly assigned to receive IMCIVREE (94 people) or a placebo (48 people), meaning they were not treated with IMCIVREE. Body mass index (BMI), a measure of body fat based on height and weight, was used to evaluate changes over time.
What was the impact of IMCIVREE?
In children and adults 4 years of age and older with acquired HO, IMCIVREE delivered significant, rapid, and sustained weight loss
After 1 year, children and adults 4 years and older taking IMCIVREE saw a reduction in BMI, while those not taking IMCIVREE saw an increase.
BMI change over 1 year
18.4%
average BMI reduction compared with those not taking IMCIVREE after 1 year
Results were consistent across age groups.
Rapid and sustained BMI reduction with IMCIVREE
- By Week 4, some people began to see reductions in their BMI
- Most people who took IMCIVREE continued to lose weight throughout the year-long clinical study
How did IMCIVREE impact BMI in adults with acquired HO?
IMCIVREE helped people 18 years and older achieve a healthier weight class
The BMI chart here shows a representation of an adult female with acquired HO and how IMCIVREE might help to lower her BMI, based on results from the clinical study.
Representative BMI chart for an adult with acquired HO before and after IMCIVREE
71%
of adults† achieved a healthier weight class after 1 year
Not an actual patient. BMI chart is for illustrative purposes only.
*BMI at the start of IMCIVREE treatment and after 1 year with IMCIVREE are average values for adults 18 years and older in the Phase 3 trial.
†27 out of 38 adults in the study. Seven people were not included in the analysis.
How did IMCIVREE impact hunger?
IMCIVREE significantly reduced hunger in people 12 years and older taking IMCIVREE compared with people not taking IMCIVREE.
Greater hunger reduction with IMCIVREE
After 1 year, people 12 years and older taking IMCIVREE reported a larger average drop in hunger scores compared with people not taking IMCIVREE.‡
How hunger was measured in the study: People 12 years and older in the study completed a daily hunger questionnaire from the start of the study through 1 year. They rated their hunger on a scale from 0 to 10, with 10 being the hungriest possible and 0 meaning not hungry at all.
Reported impact on symptoms of hyperphagia
People 12 years and older who took IMCIVREE and were able to self-report were asked questions from the Symptoms of Hyperphagia questionnaire. Based on their responses, scores measuring symptoms of hyperphagia decreased after 1 year.
This study was not designed to draw conclusions for this measurement, and these results should be interpreted with caution.
‡Scores dropped 2.3 points with IMCIVREE compared to 1.4 points without IMCIVREE, a difference of 0.8 points.
Actor Portrayals
I feel like I’m more in control. I feel like I’m making decisions, not just hunger that takes over. I feel like I can have meals and move on and not have it consume me.
– IMCIVREE patient
Individual results may vary.
How did IMCIVREE impact other health measures?
Children and adults 4 years and older taking IMCIVREE showed positive changes in:
Weight loss with IMCIVREE was also associated with a reduced waistline.
On average, children and adults taking IMCIVREE lost more inches from their waistlines compared with people who did not take IMCIVREE. Waist circumference can be used as a measure of excess fat.
This study was not designed to draw conclusions for these measurements.
How did IMCIVREE impact weight-related quality of life?
As part of this study, people with acquired HO were asked to evaluate aspects of their weight-related quality of life.
For adults, weight-related quality of life was measured using the Impact of Weight on Quality of Life-Lite Clinical Trials (IWQOL-Lite-CT) version.§ This survey asked questions related to the following areas:
- Physical
- Physical function
- Psychosocial
Adults 18 and older taking IMCIVREE saw a 30-point increase in scores on average after 1 year compared to a 4-point increase in scores in adults who did not take IMCIVREE.
This study was not designed to draw conclusions for this measurement, and these results should be interpreted with caution. An increase of at least 16.6 points in the IWQOL-Lite-CT test has been considered clinically meaningful for adults with general obesity.
§The IWQOL-Lite-CT is a validated 20-item self-report measure of obesity-specific quality of life questionnaire for adults. The questionnaire was used for assessing weight-related physical and psychosocial functioning in weight management clinical studies. Scores range from 0 to 100, with higher scores reflecting higher quality of life.
Talk to your doctor about IMCIVREE today.
Prepare for your doctor’s appointments with a discussion guide that can help you start the conversation about acquired HO and treatment with IMCIVREE.
Get personalized one-on-one support from a Patient Education Manager (PEM).¶
Learn about the possible side effects of IMCIVREE.
¶Patient Education Managers are employees of Rhythm Pharmaceuticals and do not provide medical care or advice. We encourage you to always speak to your healthcare providers regarding your medical care.